There is no registration fee for this event. However, preregistration is advised for the in-person meeting in Dallas as seating is limited. See Location tab for instructions on how to secure hotel accommodations.

---

 

Target Audience
This activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows, surgeons, radiation oncologists, pharmacists, nurse practitioners, clinical nurse specialists and other healthcare professionals involved in the treatment of cancer.

Learning Objectives
Lung Cancer Update: Antibody-Drug Conjugates and New Approaches
Upon completion of this activity, participants should be able to

• Understand the cellular targets, structural components and mechanisms of action of available and investigational antibody-drug conjugates (ADCs) with documented activity in patients with lung cancer.
• Evaluate available efficacy and safety findings with HER2-directed ADCs for patients with metastatic non-small cell lung cancer (NSCLC), and assess the optimal placement of this form of therapy in the current treatment algorithm.
• Consider the biological rationale for the development of ADCs targeting TROP2 in patients with NSCLC, and recognize available efficacy and safety findings with these agents for relapsed/refractory disease.
• Appreciate the incidence of HER3 overexpression in patients with NSCLC, and understand the rationale for and available data with HER3-directed ADCs for metastatic NSCLC with an EGFR mutation.
• Recognize the spectrum, frequency, severity and optimal management of toxicities associated with novel ADCs for lung cancer to facilitate the safe and effective current or future use of these agents.
• Recall the design of ongoing clinical trials evaluating novel ADCs or combination strategies with these agents for lung cancer, and counsel appropriate patients about availability and participation.

Leukemia and Myelodysplastic Syndromes
Upon completion of this activity, participants should be able to

• Analyze patient-specific factors and available clinical trial data guiding the selection of induction therapy for primary and secondary acute myeloid leukemia (AML) in order to optimize clinical and quality-of-life outcomes.
• Reflect on research evidence with approved FLT3 inhibitors, and use this information to guide the clinical care of appropriate patients with newly diagnosed or progressive AML harboring a FLT3 mutation.
• Evaluate the biological rationale for and available research findings with Bcl-2-targeted therapy for patients with AML or high-risk myelodysplastic syndromes (MDS), and appraise the current and potential roles of this strategy.
• Understand available efficacy and safety data with IDH1 inhibitors for patients with AML or MDS with IDH1 mutations, and integrate this novel approach into treatment algorithms.
• Recognize the scientific justification for the development of menin inhibitors for the treatment of certain genetically defined subsets of AML, and consider research findings with and the potential role of these novel agents.
• Appraise factors in the selection and sequencing of therapies for patients with chronic-phase chronic myeloid leukemia (CML), including age, comorbidities, personal preferences and side-effect profile, and offer counsel regarding personalized treatment recommendations.
• Review the mechanism of action of and published efficacy and safety data with STAMP (specifically targeting the ABL myristoyl pocket) inhibitors for patients with CML, and appreciate the current and potential role of these agents in therapy for newly diagnosed and relapsed/refractory disease.
• Assess the scientific justification for and published research findings with oral hypomethylating agent therapy for AML and MDS to determine the appropriate current clinical application of this approach.
• Review the importance of age, performance status, cytogenetic profile and other patient- and disease-related factors in the selection and sequencing of therapy for newly diagnosed MDS.
• Describe the biological rationale for, mechanism of action of and available research findings with FDA-approved agents for the treatment of anemia secondary to MDS, and evaluate how these therapies can be appropriately integrated into clinical practice.

Myelofibrosis
Upon completion of this activity, participants should be able to

• Use an understanding of disease biology and natural history to effectively counsel patients diagnosed with myelofibrosis (MF) regarding their long-term prognosis.
• Analyze how age, performance status, prior therapeutic exposure and other biological and disease-related factors affect the selection and sequencing of therapy for patients with primary and secondary MF.
• Appraise research informing the safety and efficacy of approved JAK inhibitors for patients with MF, including those with thrombocytopenia, anemia or compromised renal function.
• Review available research data with and the current clinical role of next-generation JAK inhibitors for patients with MF and severe thrombocytopenia.
• Evaluate published research findings with JAK inhibitors for patients with MF and anemia to optimize therapeutic decision-making.
• Assess available research findings with combination regimens incorporating JAK inhibitors and other novel therapies, and consider the potential clinical application of these approaches.
• Increase participation in active research protocols by counseling appropriately selected patients about the biological rationale for and available efficacy and safety data with investigational agents and strategies for MF.

Gynecologic Cancers
Upon completion of this activity, participants should be able to

• Understand available clinical research findings with PARP inhibitors as maintenance therapy after first-line platinum-based chemotherapy for advanced ovarian cancer (OC), and effectively counsel patients regarding personalized treatment recommendations.
• Evaluate the biological rationale for and published clinical research data with PARP inhibitors in combination with other systemic therapies, and consider the current and potential clinical and research implications of these findings for OC management.
• Recognize the rationale for targeting folate receptor alpha in OC, and determine the optimal role of novel approaches in therapeutically exploiting this newly relevant biomarker.
• Appreciate clinical research findings with anti-PD-1/PD-L1 antibodies in combination with chemotherapy as first-line treatment for advanced or recurrent endometrial cancer (EC), and optimally incorporate this novel strategy into the care of patients with MSI-high/MMR-deficient and microsatellite stable/MMR-proficient disease.
• Understand the biological rationale for and available and emerging data with PARP inhibitors in combination with immune checkpoint inhibitor therapy for patients with advanced or metastatic EC.
• Consider published efficacy and safety findings with anti-PD-1/PD-L1 antibodies as monotherapy or in combination with other local or systemic therapies for cervical cancer (CC), and effectively integrate immune checkpoint inhibition into patient care.
• Recognize the incidence of tissue factor (TF) expression in patients with CC, and review available research findings with and the current role of TF-directed antibody-drug conjugates.
• Evaluate published clinical research documenting the efficacy of HER2-targeted agents and regimens for patients with HER2-overexpressing EC, OC and CC, and consider the therapeutic role of various approaches.
• Describe the scientific justification for, published research data with and current studies of novel agents and strategies for OC, EC and CC, and effectively prioritize clinical trial opportunities for eligible patients.

Hepatobiliary Cancers
Upon completion of this activity, participants should be able to

• Recall clinical trial results with anti-PD-L1 antibody therapy in combination with anti-VEGF therapy for patients with hepatocellular carcinoma (HCC) and a high risk of recurrence after curative resection or ablation or for those receiving transarterial chemoembolization for unresectable disease, and consider the current and potential role of these strategies in clinical practice.
• Appreciate available and recently presented Phase III data with novel first-line treatment strategies for unresectable or metastatic HCC, and discuss how these regimens can be optimally integrated into patient care.
• Consider age, performance status, degree of liver function and other clinical and logistical factors in the selection of first-line therapy for patients with unresectable or metastatic HCC.
• Evaluate the scientific rationale for and available data with the use of anti-PD-1/PD-L1 antibodies in combination with anti-CTLA-4 antibodies for HCC, and incorporate these regimens into the management of this disease.
• Appreciate the biological justification for the evaluation of immune checkpoint inhibitors for patients with advanced biliary tract cancers, and develop strategies to optimally incorporate anti-PD-1/PD-L1 antibody-based approaches into first-line treatment.
• Assess key datasets supporting the FDA approvals of fibroblast growth factor receptor (FGFR) inhibitors for previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement in order to optimally select and sequence these agents.
• Evaluate available and emerging clinical trial findings with HER2-directed therapies for HER2-positive biliary tract cancers, and consider the current and potential utility of these agents and regimens in the care of appropriately selected patients.
• Recall available and emerging data with investigational agents and strategies currently in clinical testing for HCC and biliary tract cancers, and as applicable, refer eligible patients for trial participation.

Colorectal and Gastroesophageal Cancers
Upon completion of this activity, participants should be able to

• Optimize the use of neoadjuvant and adjuvant systemic therapy for patients with localized colorectal cancer (CRC), considering various clinical and biological factors, such as age, performance status, disease stage and microsatellite instability (MSI) or mismatch repair (MMR) status, and the potential relevance of molecular residual disease.
• Understand validated biomarkers of response found in patients with metastatic CRC (mCRC), such as RAS, BRAF, HER2, MSI or MMR deficiency and KRAS-G12C, and consider the implications for molecular testing and clinical care.
• Devise a long-term care plan for patients diagnosed with mCRC, considering biomarker profile, tumor location, prior systemic therapy, symptomatology and personal goals of treatment.
• Apply available and emerging clinical trial findings to optimize the selection and sequencing of later-line therapeutic options for patients with multiregimen-relapsed mCRC.
• Use HER2 status, PD-L1 combined positive score, MSI/MMR status, clinical factors and patient preferences to personalize the selection of first-line therapy for locally advanced or metastatic gastric, gastroesophageal junction (GEJ) and esophageal cancer.
• Describe the published research data with anti-PD-1/PD-L1 antibodies alone or in combination with other systemic therapies in the management of gastric, GEJ and esophageal cancer, and optimally integrate these strategies into nonresearch treatment algorithms.
• Evaluate the biological rationale for the investigation of claudin 18.2 as a therapeutic target in gastric/GEJ cancer, and assess available and emerging data with novel strategies directed at this potential biomarker.
• Recall clinical research data with novel HER2-targeted agents and strategies for patients with HER2-overexpressing gastric/GEJ cancer and mCRC, and optimally identify candidates for these approaches.
• Review the rationale for, available data with and ongoing research studies evaluating novel agents and strategies for CRC and gastroesophageal cancers, and effectively prioritize clinical trial opportunities for eligible patients.

CE Credit
CME, ABIM MOC, ABS and ACPE credit links will be given to each participant as part of the meeting course materials.

NCPD Credit
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

CME Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CME Credit Designation Statement
Research To Practice designates this live activity for a maximum of 6 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the participant to earn up to 6 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

American Board of Surgery (ABS) — Continuous Certification (CC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 5 Medical Knowledge MOC point toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.

Please note, this program has been specifically designed for the following ABS practice area: complex general surgical oncology.

ACPE Accreditation Statement
The University of Texas at Austin College of Pharmacy Continuing Education provided the ACPE accreditation for this course. The University of Texas at Austin College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

ACPE Credit Designation Statement
This activity is approved for up to 0.06 CEU (6 contact hours) of continuing education credit. To receive 6 contact hours of CE credit, the participant must attend each session and complete the online evaluation. Upon successful completion of the course evaluation, the continuing pharmacy education credits will automatically be uploaded to CPE Monitor (allow 3 to 4 weeks for processing).

NCPD Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

NCPD Credit Designation Statements
This educational activity for 6 contact hours is provided by Research To Practice.

This activity is awarded 6 ANCC pharmacotherapeutic contact hours.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
This program will be submitted for ONCC/ILNA certification.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

There is no implied or real endorsement of any product by Research To Practice, the Accreditation Council for Continuing Medical Education or American Nurses Credentialing Center. Any off-label use as declared by the FDA will be identified.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of a CME/NCPD accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer (physician for CME, nurse for NCPD) for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Garon — Advisory Committees and Consulting Agreements: AbbVie Inc, Arcus Biosciences, ArriVent Biopharma, AstraZeneca Pharmaceuticals LP, Atreca, Black Diamond Therapeutics Inc, BridgeBio, Bristol Myers Squibb, EMD Serono Inc, Gilead Sciences Inc, Hookipa Pharma Inc, I-Mab Biopharma, LianBio, Lilly, Merck, Merus, Novartis, Nuvalent, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Sensei Biotherapeutics, Strata Oncology, Sumitomo Dainippon Pharma Oncology Inc, Summit Therapeutics, Synthekine; Contracted Research: ABL Bio, ArriVent Biopharma, AstraZeneca Pharmaceuticals LP, BridgeBio, Bristol Myers Squibb, Daiichi Sankyo Inc, EMD Serono Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Iovance Biotherapeutics, Lilly, Merck, Mirati Therapeutics Inc, Novartis, Prelude Therapeutics, Regeneron Pharmaceuticals Inc, Synthekine, TILT Biotherapeutics; Sponsored Independent Medical Education: Daiichi Sankyo Inc; Travel: A2 Bio, Novartis. Dr Moore — Advisory Committees: Aadi Bioscience, Aravive Inc, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Caris Life Sciences, Clovis Oncology, Duality Biologics, Eisai Inc, Genentech, a member of the Roche Group, GSK, ImmunoGen Inc, Janssen Biotech Inc, Lilly, Merck, Mersana Therapeutics Inc, Myriad Genetic Laboratories Inc, Panavance Therapeutics, Regeneron Pharmaceuticals Inc, VBL Therapeutics, Verastem Inc, Zentalis Pharmaceuticals; Consulting Agreements: Aadi Bioscience, Caris Life Sciences, Duality Biologics, Eisai Inc, Mersana Therapeutics Inc, Regeneron Pharmaceuticals Inc; Contracted Research: Genentech, a member of the Roche Group, GSK, Lilly, PTC Therapeutics. Additional faculty to be announced.

MODERATOR
Dr Divers — No relevant conflicts of interest to disclose.

Research To Practice CME/NCPD Planning Committee Members, Staff and Reviewers
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
To be announced.

The Ritz-Carlton Dallas, Las Colinas
4150 N MacArthur Blvd
Irving, TX 75038
Hotel Phone: (972) 717-0700

Meeting Room
Lantana Ballroom — Lobby Level

Hotel Room Reservations

• American Oncology Network (AON) members, please be sure to book accommodations in the AON room block.
•  
• For all other registrants, room reservation information will be included in the confirmation email after you have registered for this program.

 

Map: